Patent Application
20160030493
The present invention relates to the treatment, medicaments and use of particular compositions for manufacture thereof, for use against the progression of, or regression from dementia and neurodegenerative diseases such as Alzheimer disease.
Alzheimer's disease (AD), is a major form of dementia that affects memory, thinking, and behavior, and gradually worsens over time.
There are two types of AD:
The cause of late AD is not clear. Our genes and environmental factors seem to play a role. See for example: http://www.ncbi.nlm nih.gov/pubmedhealth/PMH0001767 (1).
Epigallocatechin-3-gallate (EGCG) the main polyphenolic constituent of green tea, has been shown in numerous studies to be a highly effective antioxidant, by reacting with the majority of reactive oxygen species (ROS) (2).
It was also suggested that in addition to its radical scavenging, chelation of redox active metals such as iron, and regulation of antioxidant protective enzymes, can be part of the protective effect of EGCG against neuronal diseases (3). Indeed, the chemical pathologies of AD and of Parkinson disease (PD) show many similarities, including increased iron concentration in addition to oxidative stress (3).
Experimental work with green tea and EGCG also indicates that orally ingested polyphenols can reach the brain, and exert neuroprotective effects (3). In fact, in-vitro studies showed that EGCG prevented the formation of β-sheet rich aggregation products, such as amyloid fibrils, that are associated with the development of AD and PD, leading the authors to conclude that EGCG could be useful for therapy against development of these diseases(4).
In a different study it was shown that EGCG reduces the generation of β-amyloid peptides, raising the possibility that EGCG dietary supplementation may provide effective prophylaxis for AD (5). Furthermore, in a study which examined the association between green tea consumption and cognitive function, it was shown that higher consumption of green tea is associated with lower prevalence of cognitive impairment in humans, supporting the potential benefit of green tea and EGCG in preventing neurodegenerative diseases (6).
The grape seed extract (GSE) is a water extract of grape seeds, for example Meganatural-BP® produced by Polyphenolics Inc. (7). The extract is comprised of polyphenol monomers, oligomers and polymers of catechin and of epicatechin (8, 9). EGCG and the polyphenols in GSE belong to a similar family of polyphenols, yet they are chemically distinct. Consumption of this particular GSE (produced by Polyphenolics Inc.) in a clinical study was found to reduce both the systolic and diastolic blood pressures (10).
A different study demonstrated that the same GSE product prevented amyloid β-protein aggregation into high molecular weight (HMW) oligomers, in-vitro, and when administrated orally to mice that serve as a model for AD, the GSE attenuated AD type cognitive deterioration, coincidentally with reduced HMW (High Molecular Weight) soluble oligomeric amyloid β in the brain (11).
A recent study (12) shows that certain strains of lactic acid bacteria, when consumed orally as probiotics, like the specific strain Lactobacillus plantarum, possess enzymes that can effectively breakdown polyphenols and tannins into smaller metabolites, that are more easily absorbed from the intestine into the blood stream. Such bacteria need to be protected from gastric conditions.
It should be further noted that capsules named “DRCAPS™ capsules”, a product of “Capsugel”, are used to house and protect the active ingredients (13), and consist of the acid resistant polymer, hydroxypropyl methylcellulose. In vitro studies showed that the capsule's contents are protected for at least 20 min under gastric conditions and are fully released at an intestinal pH of 6.8 (13). This delayed release essentially protects the capsule's ingredients from the harsh environment in the stomach.
According to one aspect, a medicament comprising EGCG and GSE is provided.
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description. The invention is capable of other embodiments or of being practiced or carried out in various ways.
The terms “comprises”, “comprising”, “includes”, “including”, and “having” together with their conjugates mean “including but not limited to”.
The term “consisting of” has the same meaning as “including and limited to”. The term “consisting essentially of” means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
As used herein, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a compound” or “at least one compound” may include a plurality of compounds, including mixtures thereof.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials and methods are illustrative only and not intended to be limiting.
No attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.
Preparations and applications of medicaments comprising at least two of EGCG, GSE and L. plantarum are provided, that, surprisingly synergistically improve mental abilities such as memory and are thus thought to also inhibit or at least reduce the progression of diseases such as Alzheimer disease or PD. Preferably, the medicament comprises at least EGCG and GSE.
Meganatural-BP® is 300 mg GSE provided in HPMC (hydroxypropylmethyl cellulose) capsules (DR caps®) of Capsugel, which are gastric-resistant and mostly disintegrate in the small intestine.
EGCG (Lyan, China) and Lactobacillus plantarum R1012-150 (Institut Rosell, Canada) DR Caps capsules were prepared. The average amount of Lactobacillus plantarum per capsule was 377 mg/capsule (about 6*1010 bacteria). The bacteria should be kept in cool conditions—about 5° C. The average amount of EGCG was 218 mg. The EGCG is produced by water/EtOH extraction from leaves of locally cultivated camellia sinensis O. Ktze.
The catechins content in the EGCG is preferably at least 95%. The content of polyphenols in GSE is preferably at least 90%.
Green tea and grape seed extracts as well as bacteria from other suppliers are considered to have an effect similar to that from these material sources.
The minimum effective dosage of GSE per day is considered to be about 100 mg, and the minimum effective dosage of EGCG is about 50 mg per day; the dosage depends upon the severity of the condition and the patient's general state of health, as well as weight and other considerations familiar to the practitioner.
It is notable that although full clinical trials involve control by placebo, the preliminary results from treatment of a patient suffering from AD, described below, are absent this control. However, such control is perhaps of little relevance since, to the best of the inventors' knowledge no reliable and perceptible change would be observed in administration of placebos to such patients having cognitive impairment.
Since the polyphenols generally react with proteins, the administration is best performed on an empty stomach.
A first subject consumed a capsule containing 300 mg of Meganatural-BP® over a period of 18 months, once daily, immediately after nocturnal sleep. Some improvement of memory was observed during the period that the GSE was administered, compared to memory ability before the administration commenced.
General Effect of EGCG on mental faculties The same subject ceased to consume GSE and immediately subsequent consumed capsules of 100 mg EGCG (Lyan) over a period of 40 days, once daily, immediately after nocturnal sleep.
No improvement of memory was observed during the period that the EGCG was administered.
300 mg of Meganatural-BP® and 60 mg of EGCG capsules were concomitantly administered to the same subject, immediately after nocturnal sleep, following the EGCG regime.
There was a pronounced improvement of long-term memory which had not been previously observed by an observation group as well as by the subject. The improvements were both in the level of detail and in the completeness of the memory. For example, location/people details of a family trip were recalled that no other members of the family nor indeed the subject himself could previously recall; details of an artwork observed over 40 years previously by the subject and a group of people were recalled in minute details, including the location of the creation, shape and its colors, whereas none of the members of the group could recall any of these details.
The subject also reported feeling generally physically well and more lucid in mind.
It is noteworthy that three months into the combined GSE and EGCG regime, the subject was found to have below normal levels of folic acid. It is known that there is a positive correlation between folic acid and memory, thus the apparent improvement in memory may be despite folic acid deficiency.
A hypertensive and diabetic 82 year old male exhibited a cognitive deterioration and subsequently (after about a year) underwent mini-mental state examination (MMSE) which produced a grade of 13; thus the patient was diagnosed as suffering from Alzheimer disease.
Six weeks after the diagnosis, the patient's condition continued to deteriorate. The patient was administered memantine hydrochloride (Ebixa® tablet), an antidementia medicine, on a daily basis. Blood-pressure reducing medication was concomitantly administered and the blood pressure was measured to be on the average of 130/70 systolic/diastolic. However, the patient's deterioration appeared to be unaffected by the drug and administration of Ebixa was consequently discontinued after two weeks.
The following four months were characterized by sporadic memory lapses typical of a moderately severe affliction as well as behavioral deteriorations that occurred from time to time
At this point of time, according to a 60 days plan, the patient was daily administered two Meganatural-BP® capsules (600 mg), one 218 mg EGCG capsule (Lyan) and one L. plantarum capsule(377 mg), as well as blood-pressure reducing medication.
About 18 days after the administration (of the GSE. EGCG, and bacteria) was initiated, the blood pressure dropped to about 70-80/50.
Consequently, the blood-pressure reducing medication was discontinued and the administration of GSE was reduced to one capsule per day (300 mg) as GSE is known to reduce blood pressure.
Two weeks (14 days) thereafter the reduction of blood pressure, the deterioration appeared to have halted.
During the next two weeks, a gradual improvement of the mental capacities such as memory-related performance was observed.
In the next two weeks, a significant improvement in the cognitive state of the patient was observed and his mental state started to become more stable. Regression of the disease was noted.
At this point, the GSE, EGCG, and bacteria were discontinued and the patient's mental capacities appeared to have dramatically improved compared to his condition just prior to the administration of the GSE, EGCG and probiotic bacteria, in particular his ability to follow a clock and sense time appeared to have been restored and there were no memory lapses.
No adverse effects on blood sugar were observed during and after the treatment.
Slight memory lapses were observed subsequent to the discontinuation, and a repeat MMSE performed 3 weeks later gave a grade of 19, which is still a highly significant improvement over the patient's performance in the MMSE prior to the administration of GSE, EGCG, and bacteria.
It should be mentioned that Cipralex®, a drug against depression and anxiety, as well as other calming drugs were administrated to the patient prior and during the administration of the GSE, EGCG, and bacteria according to need.
The GSE may be the extract described in any of the patents U.S. Pat. No. 7,767,235, U.S. Pat. Nos. 7,651,707 and 6,544,581, and may be prepared according to the process described in U.S. Pat. No. 8,075,929; however, other similar preparations and processes may be investigated whether they contribute to a similar synergistic effect, for example more particular ingredients of the GSE may be used.
The capsules may comprise both the bacteria and the GSE and/or EGCG; having all the components together may simplify the medication regime; however, it may be that the GSE and/or EGCG reduce the effectiveness of the medication, presumably due to an adverse interaction of substances in the GSE/EGCG with the bacteria. Therefore, in some embodiments the bacteria are separately provided in gastric-resistant capsules or other dosage forms.
In other embodiments the bacteria and/or GSE/EGCG extracts (either or both) are enteric coated, and are provided as enteric-coated granules within one dose, e.g. capsule. Presumably the bacteria perform most of their beneficial activity in the large intestine; and most of the bacteria are likely to arrive there intact when protected from the gastric conditions in the stomach.
Alternatively, the bacteria and the polyphenols may be provided in separate compartments. Such segmented capsules/pills may be manufactured by 3-D printing for example, with the materials therein, or added after the pill/capsule is ready.
Other forms of delivery may be used instead of or in addition to capsules, including but not limited to nutraceuticals, tablets, suspensions, suppositories (liquid or solid), injectable/intravenous solutions and lotions. The solid forms of delivery may be at least partially 3-D printed.
Some embodiments further comprise flavourings and/or food stuff, to help consume the materials. The foodstuff is preferably low-protein.
In some embodiments the bacteria are physically separated or functionally isolated from the EGCG and GSE extracts until they all arrive at the intestines; or at least they remain as separate as possible until arrival at the large intestine. Polysaccharide coating of the GSE, EGCG and bacteria, or at least the bacteria, may help delay the interaction until the optimal time.
Surprising synergy of the (presumably polyphenolic) ingredients in grape seed and green tea extracts has been demonstrated for improvement of mental condition or at least helping to reduce mental deterioration, in particular when properly used in conjuction with probiotic bacteria that are thought (without being bound to the theory) to provide metabolic products with improved efficacy. Other synergies that are considered likeliest are between the GSE and/or green-tea EGCG and polyphenolic extracts from other plant sources, in particular from pomegranates, dates, and various berries or vitamin E. other oxidants or polyphenols can be used without limiting the scope of the invention.
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/IL2014/050265 | 3/13/2014 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 61781761 | Mar 2013 | US |
